Enquadramento: A psilocibina, composto psicoativo de cogumelos Psilocybe, tem sido estudada pelo potencial terapêutico em perturbações neuropsiquiátricas [1]. Contudo, continuam escassos os dados pré-clínicos que comparem psilocibina isolada e extratos integrais, sobretudo quanto ao reforço comportamental e toxicidade periférica [2,3]. Objetivo: Comparar os efeitos comportamentais e...
Enquadramento: A psilocibina, composto psicoativo principal de cogumelos Psilocybe, tem suscitado interesse pelo potencial terapêutico em perturbações neuropsiquiátricas [1]. Para além dos efeitos centrais, a evidência sobre o eixo intestino-cérebro sugere que os psicadélicos podem influenciar a microbiota intestinal. Extratos integrais contêm compostos bioativos adicionais, mas os dados...
Introduction: Psilocybin, the main psychoactive compound in Psilocybe mushrooms, has attracted interest for its potential therapeutic effects in neuropsychiatric disorders (Erkizia-Santamaría et al., 2025). However, preclinical data comparing its behavioral properties to whole mushroom extracts remain limited (Ali et al., 2023; Johnson-Groh, 2025). Objective: To investigate the reinforcing and...
Background: Psilocybin, the main psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its potential therapeutic effects in neuropsychiatric disorders [1]. Beyond its central effects, increasing evidence highlights the relevance of the gut–brain axis, suggesting that psychedelics may also influence intestinal microbiota composition. Whole mushroom extracts...
Background: Psilocybin, a key psychoactive compound found in Psilocybe mushrooms, has gained increasing attention due to its therapeutic potential in neuropsychiatric disorders [1]. However, comparative preclinical data between isolated psilocybin and whole mushroom extracts remain scarce, particularly regarding behavioural reinforcement and peripheral toxicity [2,3]. Objective: To compare the...